What Happens to My Treatment if Compounding Rules Change?

On April 30, 2026, the FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List ^{1 2}. That list governs outsourcing facilities, the large-batch route that compounds from bulk drug substances. It is a separate framework from 503A compounding, where a state-licensed pharmacy prepares a medication for one named patient under a prescription written for that person ⁵.

So if your medication is a 503A patient-specific compounded preparation, this particular proposal is aimed at a different lane. That is the single most important thing to understand before you worry.

The legal opening for a lot of bulk compounding was the drug shortage. When a medication is in shortage, the rules widen. The FDA has since declared those shortages resolved: tirzepatide in December 2024 and semaglutide in February 2025 ⁴. In the new proposal, the agency says it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances ¹.

Read this on its own line, because it is the whole point:

The shortage justification ended, and this proposal is aimed at the bulk outsourcing route.

Here is the part that gets lost in the noise. Even in the situation where a future rule did reach some form of compounding, you would not be out of options. Branded GLP-1 medications stay on the market, and a prescribing clinician can move a patient onto a branded product when that is the right call.

A compounded preparation and a branded drug are different products, prepared and approved through different routes. Compounded drugs are not FDA-approved ⁵. So a switch is a clinical decision your physician makes with you. It is never a like-for-like swap.

The point is continuity. A change in one supply route does not mean the door closes. It means a clinician helps you find the next door.

This is where the brand you choose either earns your trust or loses it. A provider built for the long haul does not wait for you to panic at a headline. They watch the regulatory landscape, they tell you which lane your medication comes from, and they have a plan for moving you to a branded option if a rule ever reaches your treatment, without a gap in care and without a surprise on your card.

The standard to demand is simple. Ask whether your provider will tell you plainly whether your medication is a 503A patient-specific compounded preparation or a branded product. Ask whether they will never call a compounded medication a generic copy of a brand or claim it is the same as the brand. And ask to see the terms before your card is charged: full cost disclosed before checkout, recurring monthly charge until canceled, cancel anytime in your account, no phone call required. A provider who can answer all of that is one that plans for change instead of being surprised by it. (This is the standard sipra was built around.)

The proposal is a notice about the 503B list, not a change to a patient-specific prescription. Its comment period was extended to July 30, 2026 ³, and any final decision would come through a formal process. The honest move is to stay informed and keep your clinician in the loop, not to rush a decision. Your physician and your pharmacy are the right people to tell you how any future rule would reach your specific treatment, because that is a clinical and regulatory call, not a blog call.

Ask your current or prospective provider one direct question: if the rules change, what is your plan to keep my treatment going without a gap? A provider who has a clear, calm answer is the one to keep. That kind of steady continuity is exactly what sipra is built to give.